KONICA MINOLTA 3rdQuarter/FY2017 ending in March 2018 Consolidated Financial Results  


3Q New Business Progress : Precision Medicine

Prev. Page Next Page Download the PDF
Next, I will give an update on the progress of our entry into the precision medicine business.
In order to realize a full-fledged entry into the precision medicine business, Konica Minolta acquired Ambry Genetics Corporation, with the acquisition process completed in October. The acquisition of Invicro LLC was completed in November, and the two became consolidated subsidiaries. In order to formulate and implement strategic global plans in conjunction with Konica Minolta human capital and technology, as well as to formulate and implement business strategy for the US and other regions, we have established our Precision Medicine Headquarters in the US. Senior Executive Officer and General Manager Kiyotaka Fujii of the Healthcare Business Headquarters has taken up the position of CEO, with Senior Executive Officer Kunihiro Koshizuka, who is responsible for Technologies as CTO. In January, they held a joint town hall meeting with all the employees, creating an occasion that conveyed their enthusiasm and determination to operate as a single, integrated entity. That mission and vision of Konica Minolta human capital and HSTT technology united with the human capital and technology from Ambry and Invicro was shared by all, and fully fledged integrated operation has begun.